38514176|t|Clinicoradiological and neuropathological evaluation of primary progressive aphasia.
38514176|a|BACKGROUND: Primary progressive aphasia (PPA) defines a group of neurodegenerative disorders characterised by language decline. Three PPA variants correlate with distinct underlying pathologies: semantic variant PPA (svPPA) with transactive response DNA-binding protein of 43 kD (TDP-43) proteinopathy, agrammatic variant PPA (agPPA) with tau deposition and logopenic variant PPA (lvPPA) with Alzheimer's disease (AD). Our objectives were to differentiate PPA variants using clinical and neuroimaging features, assess progression and evaluate structural MRI and a novel 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) image decomposition machine learning algorithm for neuropathology prediction. METHODS: We analysed 82 autopsied patients diagnosed with PPA from 1998 to 2022. Clinical histories, language characteristics, neuropsychological results and brain imaging were reviewed. A machine learning framework using a k-nearest neighbours classifier assessed FDG-PET scans from 45 patients compared with a large reference database. RESULTS: PPA variant distribution: 35 lvPPA (80% AD), 28 agPPA (89% tauopathy) and 18 svPPA (72% frontotemporal lobar degeneration-TAR DNA-binding protein (FTLD-TDP)). Apraxia of speech was associated with 4R-tauopathy in agPPA, while pure agrammatic PPA without apraxia was linked to 3R-tauopathy. Longitudinal data revealed language dysfunction remained the predominant deficit for patients with lvPPA, agPPA evolved to corticobasal or progressive supranuclear palsy syndrome (64%) and svPPA progressed to behavioural variant frontotemporal dementia (44%). agPPA-4R-tauopathy exhibited limited pre-supplementary motor area atrophy, lvPPA-AD displayed temporal atrophy extending to the superior temporal sulcus and svPPA-FTLD-TDP had severe temporal pole atrophy. The FDG-PET-based machine learning algorithm accurately predicted clinical diagnoses and underlying pathologies. CONCLUSIONS: Distinguishing 3R-taupathy and 4R-tauopathy in agPPA may rely on apraxia of speech presence. Additional linguistic and clinical features can aid neuropathology prediction. Our data-driven brain metabolism decomposition approach effectively predicts underlying neuropathology.
38514176	56	83	primary progressive aphasia	Disease	MESH:D018888
38514176	97	124	Primary progressive aphasia	Disease	MESH:D018888
38514176	126	129	PPA	Disease	MESH:D018888
38514176	150	177	neurodegenerative disorders	Disease	MESH:D019636
38514176	195	211	language decline	Disease	MESH:D007806
38514176	219	222	PPA	Disease	MESH:D018888
38514176	297	300	PPA	Disease	MESH:D018888
38514176	302	307	svPPA	Disease	MESH:D018888
38514176	314	363	transactive response DNA-binding protein of 43 kD	Gene	23435
38514176	365	371	TDP-43	Gene	23435
38514176	407	410	PPA	Disease	MESH:D018888
38514176	412	417	agPPA	Disease	MESH:D018888
38514176	424	427	tau	Disease	MESH:C536599
38514176	461	464	PPA	Disease	MESH:D018888
38514176	466	471	lvPPA	Disease	MESH:D018888
38514176	478	497	Alzheimer's disease	Disease	MESH:D000544
38514176	499	501	AD	Disease	MESH:D000544
38514176	541	544	PPA	Disease	MESH:D018888
38514176	655	678	18-F fluorodeoxyglucose	Chemical	MESH:D019788
38514176	709	712	FDG	Chemical	MESH:D019788
38514176	830	838	patients	Species	9606
38514176	854	857	PPA	Disease	MESH:D018888
38514176	1061	1064	FDG	Chemical	MESH:D019788
38514176	1083	1091	patients	Species	9606
38514176	1143	1146	PPA	Disease	MESH:D018888
38514176	1172	1177	lvPPA	Disease	MESH:D018888
38514176	1183	1185	AD	Disease	MESH:D000544
38514176	1191	1196	agPPA	Disease	MESH:D018888
38514176	1202	1211	tauopathy	Disease	MESH:D024801
38514176	1220	1225	svPPA	Disease	MESH:D018888
38514176	1231	1288	frontotemporal lobar degeneration-TAR DNA-binding protein	Disease	MESH:D057174
38514176	1290	1298	FTLD-TDP	Disease	MESH:D057180
38514176	1302	1319	Apraxia of speech	Disease	MESH:D001072
38514176	1340	1352	4R-tauopathy	Disease	MESH:D024801
38514176	1356	1361	agPPA	Disease	MESH:D018888
38514176	1374	1388	agrammatic PPA	Disease	MESH:D018888
38514176	1397	1404	apraxia	Disease	MESH:D001072
38514176	1419	1431	3R-tauopathy	Disease	MESH:D024801
38514176	1460	1480	language dysfunction	Disease	MESH:D007806
38514176	1518	1526	patients	Species	9606
38514176	1532	1537	lvPPA	Disease	MESH:D018888
38514176	1539	1544	agPPA	Disease	MESH:D018888
38514176	1556	1611	corticobasal or progressive supranuclear palsy syndrome	Disease	MESH:D013494
38514176	1622	1627	svPPA	Disease	MESH:D018888
38514176	1662	1685	frontotemporal dementia	Disease	MESH:D057180
38514176	1699	1711	4R-tauopathy	Disease	MESH:D024801
38514176	1734	1766	supplementary motor area atrophy	Disease	MESH:D017034
38514176	1768	1776	lvPPA-AD	Disease	MESH:D018888
38514176	1796	1803	atrophy	Disease	MESH:D001284
38514176	1850	1855	svPPA	Disease	MESH:D018888
38514176	1856	1864	FTLD-TDP	Disease	MESH:D057180
38514176	1876	1897	temporal pole atrophy	Disease	MESH:D001284
38514176	1903	1906	FDG	Chemical	MESH:D019788
38514176	2040	2042	3R	Disease	
38514176	2043	2051	taupathy	Disease	
38514176	2056	2068	4R-tauopathy	Disease	MESH:D024801
38514176	2072	2077	agPPA	Disease	MESH:D018888
38514176	2090	2107	apraxia of speech	Disease	MESH:D001072
38514176	Association	MESH:D018888	23435

